Martin Capital Advisors LLP Buys 128 Shares of Edwards Lifesciences Co. (NYSE:EW)

Martin Capital Advisors LLP grew its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 0.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 25,490 shares of the medical research company’s stock after buying an additional 128 shares during the quarter. Edwards Lifesciences accounts for approximately 1.6% of Martin Capital Advisors LLP’s holdings, making the stock its 19th largest position. Martin Capital Advisors LLP’s holdings in Edwards Lifesciences were worth $1,944,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Nordea Investment Management AB increased its holdings in Edwards Lifesciences by 1,224.1% during the fourth quarter. Nordea Investment Management AB now owns 1,610,412 shares of the medical research company’s stock valued at $123,261,000 after buying an additional 1,488,791 shares during the last quarter. Telos Capital Management Inc. increased its stake in shares of Edwards Lifesciences by 158.2% in the 4th quarter. Telos Capital Management Inc. now owns 91,405 shares of the medical research company’s stock worth $6,970,000 after purchasing an additional 56,000 shares in the last quarter. Arlington Trust Co LLC raised its holdings in Edwards Lifesciences by 5,092.4% in the 4th quarter. Arlington Trust Co LLC now owns 12,306 shares of the medical research company’s stock worth $938,000 after purchasing an additional 12,069 shares during the period. Versor Investments LP lifted its position in Edwards Lifesciences by 83.3% during the third quarter. Versor Investments LP now owns 4,496 shares of the medical research company’s stock valued at $311,000 after purchasing an additional 2,043 shares in the last quarter. Finally, HealthInvest Partners AB bought a new stake in Edwards Lifesciences during the fourth quarter valued at about $1,587,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

EW has been the topic of several recent analyst reports. Truist Financial raised their price objective on shares of Edwards Lifesciences from $78.00 to $84.00 and gave the company a “buy” rating in a research report on Friday, December 22nd. Citigroup increased their price objective on shares of Edwards Lifesciences from $90.00 to $98.00 and gave the company a “neutral” rating in a report on Wednesday, April 3rd. Mizuho boosted their target price on shares of Edwards Lifesciences from $95.00 to $105.00 and gave the stock a “buy” rating in a report on Thursday, April 11th. OTR Global raised Edwards Lifesciences from a “mixed” rating to a “positive” rating in a report on Tuesday, March 26th. Finally, Stifel Nicolaus lifted their price target on shares of Edwards Lifesciences from $70.00 to $83.00 and gave the stock a “hold” rating in a research note on Wednesday, February 7th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $91.73.

Insider Transactions at Edwards Lifesciences

In other news, CFO Scott B. Ullem sold 7,255 shares of the firm’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $78.29, for a total value of $567,993.95. Following the completion of the sale, the chief financial officer now owns 19,248 shares in the company, valued at approximately $1,506,925.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Edwards Lifesciences news, SVP Robert W.A. Sellers sold 12,210 shares of the firm’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $87.00, for a total value of $1,062,270.00. Following the completion of the sale, the senior vice president now owns 13,087 shares of the company’s stock, valued at $1,138,569. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Scott B. Ullem sold 7,255 shares of the stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $78.29, for a total transaction of $567,993.95. Following the completion of the transaction, the chief financial officer now owns 19,248 shares of the company’s stock, valued at approximately $1,506,925.92. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 194,004 shares of company stock worth $17,166,254. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Down 0.6 %

NYSE:EW traded down $0.51 during mid-day trading on Friday, hitting $85.94. The stock had a trading volume of 3,870,655 shares, compared to its average volume of 3,865,306. The company has a market capitalization of $51.73 billion, a PE ratio of 37.37, a PEG ratio of 4.32 and a beta of 1.05. The stock has a 50-day simple moving average of $90.14 and a two-hundred day simple moving average of $78.19. Edwards Lifesciences Co. has a twelve month low of $60.57 and a twelve month high of $96.12. The company has a current ratio of 3.38, a quick ratio of 2.40 and a debt-to-equity ratio of 0.09.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Tuesday, February 6th. The medical research company reported $0.64 earnings per share for the quarter, hitting the consensus estimate of $0.64. Edwards Lifesciences had a return on equity of 23.56% and a net margin of 23.35%. The firm had revenue of $1.53 billion during the quarter, compared to analysts’ expectations of $1.50 billion. During the same quarter in the previous year, the business earned $0.64 earnings per share. The firm’s revenue was up 13.3% compared to the same quarter last year. On average, equities research analysts anticipate that Edwards Lifesciences Co. will post 2.76 EPS for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.